本帖最后由 老马 于 2012-1-13 21:20 编辑
S& }# Z! j& u# E' L1 B% \. _) H; X+ Y6 H
爱必妥和阿瓦斯丁的比较
, ]" `% s8 C6 U% {9 Z
% s4 y5 K" r; ~5 K: G* @6 \& R/ E$ I
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
( C- M {4 m) P( U/ j, v8 }9 |
1 r+ ~8 q% q$ T' w5 c+ u1 B: |
# e- a# C/ @, a3 x, K1 S
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, {, v& J, T6 O( q7 j- ^; w5 @
==================================================+ r$ u( m( k7 t: s9 L8 ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! |3 c' N. h$ z2 p- P1 u
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& u$ Z6 h; w# v3 b8 v3 d& @3 DResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 D2 V. m* h$ f6 {; F4 ^
|